Regencell Bioscience Holdings Ltd

RGC Nasdaq SEC CIK 1829667
Follow Regencell Bioscience Weekly email: filings, results

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearNet income
FY26−$11.7M
FY25−$3.6M
FY24−$4.3M
FY23−$5.9M
FY22−$7.4M
FY21-
FY20−$812.4K
FY19−$391K
Free cash flowOperating cash flow minus capital expenditure
−$8M−$6M−$4M−$2M$0FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearFree cash flow
FY26-
FY25−$3.3M
FY24−$4M
FY23−$5M
FY22−$6M
FY21-
FY20−$844.4K
FY19-